Is Low Libido in Women Hormonal?

How Hormones Drive Female Sexual Desire

Hormones are the most consistently documented biological drivers of female sexual desire, acting on both brain reward circuitry and genital tissue. Estrogen, testosterone, and progesterone each affect libido through separate mechanisms, and their levels shift significantly across the menstrual cycle, postpartum recovery, perimenopause, and surgical menopause. Identifying which hormone is off, and by how much, is the first step any clinical evaluation should take.

Testosterone receives the least attention in women's health despite being measurable, treatable, and closely tied to desire. Women produce testosterone in the ovaries and adrenal glands, reaching peak serum levels (roughly 70 ng/dL total testosterone) in the early 20s before declining steadily 1. By the late 30s, many women have lost nearly half their peak testosterone. A 2019 systematic review and meta-analysis published in the Lancet Diabetes and Endocrinology (36 randomized controlled trials, N=8,480) concluded that testosterone therapy "significantly improved sexual function, including desire, arousal, orgasm, and pleasure," with the most consistent effect on desire in postmenopausal women 2.

Estrogen works differently. It keeps vaginal tissue well-perfused, lubricated, and pain-free. When estrogen falls sharply at menopause, the resulting genitourinary syndrome (GSM) produces dryness, thinning, and dyspareunia in up to 45% of postmenopausal women 3. Pain during sex extinguishes desire faster than almost any other single factor. Low estrogen also reduces dopaminergic tone in the medial preoptic area of the hypothalamus, directly blunting the neurological drive toward sexual initiation 4.

Progesterone's role is subtler. High progesterone in the luteal phase is associated with decreased sexual motivation in some women, and the synthetic progestins used in combined oral contraceptives may lower sex hormone-binding globulin (SHBG) paradoxically, raising SHBG and thereby reducing free testosterone 5. That SHBG elevation can persist for months after stopping the pill.

What Is HSDD and How Is It Diagnosed?

Hypoactive Sexual Desire Disorder (HSDD) is the clinical label for low sexual desire that causes the patient personal distress and is not explained by a co-occurring medical or psychiatric condition. It is the most common female sexual dysfunction, estimated to affect approximately 10% of adult women in community samples 6.

The American Psychiatric Association's DSM-5 merged HSDD with female sexual arousal disorder into a single category called Female Sexual Interest/Arousal Disorder (FSIAD), though many clinicians and clinical trials still use the HSDD label because its diagnostic criteria are operationally precise 7. Diagnosis requires that low desire be persistent or recurrent, present for at least 6 months, and cause the patient meaningful distress. Laboratory values are not part of the formal DSM-5 criteria. However, the Endocrine Society's 2014 clinical practice guideline on female sexual dysfunction recommends measuring total and free testosterone, thyroid-stimulating hormone, prolactin, and fasting glucose before attributing low desire solely to psychological causes 8.

A practical three-step clinical screening approach used by HealthRX clinicians:

1. Confirm distress. Low desire without distress is a normal variant, not a disorder. Validated tools include the Female Sexual Function Index (FSFI) and the Decreased Sexual Desire Screener (DSDS).
2. Rule out reversible pharmacologic causes. SSRIs, SNRIs, antipsychotics, spironolactone, and combined oral contraceptives are among the most common libido suppressants seen in outpatient practice.
3. Test hormones in context. A serum total testosterone below 25 ng/dL in a premenopausal woman, or below 10 ng/dL in a postmenopausal woman, warrants clinical attention even though no universally agreed female reference range exists 8.

Does HRT Increase Libido in Women?

Estrogen-based HRT reliably improves libido when low desire is driven primarily by estrogen deficiency and its downstream consequences (vaginal atrophy, dyspareunia, sleep disruption). The evidence is strongest in surgically menopausal women, where estrogen loss is abrupt. A Cochrane review of 23 trials found that estrogen therapy significantly reduced dyspareunia and vaginal dryness compared with placebo, outcomes directly linked to improved sexual comfort and, secondarily, desire 9.

Estrogen alone, though, does not restore testosterone-driven spontaneous desire in most women. The WISDOM trial and several smaller RCTs suggest that adding testosterone to estrogen HRT produces a meaningfully larger improvement in sexual desire scores than estrogen alone 2. The North American Menopause Society's 2022 position statement on hormone therapy states that testosterone, used in combination with or independent of conventional HRT, "has the most evidence for treating HSDD in postmenopausal women" 10.

Oral estrogens raise SHBG more than transdermal formulations, which can lower free testosterone even when total testosterone appears normal. Switching from oral to transdermal estradiol is a low-risk first step for women on HRT who notice worsening libido without an obvious cause 11.

Can Testosterone Therapy Help Women's Libido?

Testosterone therapy is the most evidence-backed pharmacological treatment for HSDD in women, despite the absence of any FDA-approved female testosterone product in the United States. Clinicians prescribe male-formulation testosterone gels, creams, or pellets at doses calibrated to female physiology, typically targeting a total testosterone of 40 to 60 ng/dL rather than the male range of 300 to 1 to 000 ng/dL 2.

The APHRODITE trial (N=814 to 52 weeks) tested a 300-mcg/day testosterone patch in naturally menopausal women not on estrogen. The patch produced a statistically significant increase in satisfying sexual events (SSEs) compared with placebo: 2.1 more SSEs per 4 weeks vs. 0.7 placebo (P<0.001), along with improved desire scores on the FSFI 12. A separate patch trial (N=556 to 24 weeks) in postmenopausal women on concurrent estrogen therapy showed a mean increase of 2.1 SSEs per 4-week period in the 300-mcg group versus 0.98 in the placebo group (P<0.001) 13.

Short-term safety data from these trials and the 2019 Lancet meta-analysis show no significant increase in androgenic adverse events (acne, hirsutism, voice changes) at physiological doses 2. Long-term cardiovascular and breast-cancer data beyond 2 years are limited, and the Endocrine Society recommends monitoring serum testosterone every 6 months and stopping therapy if levels exceed the normal female range 8.

Testosterone therapy is generally not recommended during pregnancy or for women with active hormone-sensitive cancers. Baseline PSA testing is not required for women, but a lipid panel before initiation is standard practice given the theoretical effect of androgens on HDL cholesterol 8.

Non-Hormonal Causes of Low Libido That Mimic Hormonal Dysfunction

Not every case of low desire is hormonal. Several common conditions produce a clinical picture nearly identical to testosterone or estrogen deficiency, and missing them leads to ineffective treatment.

Thyroid dysfunction. Both hypothyroidism and hyperthyroidism reduce sexual desire. TSH should be measured in any woman presenting with fatigue plus low libido, as the symptom overlap is high 14.

Antidepressant use. SSRIs and SNRIs reduce libido in 30 to 40% of users by blocking dopamine reuptake and elevating serotonin tone in limbic circuits 15. Switching to bupropion (a norepinephrine-dopamine reuptake inhibitor) or adding bupropion 150 to 300 mg/day has demonstrated partial libido recovery in multiple small RCTs 16.

Hormonal contraceptives. Combined oral contraceptives raise SHBG by 3 to 4 times baseline, which drops free testosterone measurably. A 2006 cross-sectional study (N=124) found that women using oral contraceptives had SHBG levels 4 times higher and free testosterone levels 60% lower than non-users 5.

Hyperprolactinemia. Elevated prolactin, whether from a pituitary adenoma, chronic stress, or dopamine-blocking medications, suppresses GnRH and reduces both estrogen and testosterone production 17. A simple fasting morning prolactin level can rule this out.

Relationship and psychological factors. Attachment insecurity, unresolved conflict, and depression each independently reduce desire scores on validated instruments. A 2010 prospective cohort study found that depressive symptoms predicted low desire 2 years later independent of hormone levels 18.

Clinicians at HealthRX conduct a structured differential that tests hormones and screens for psychiatric and pharmacologic contributors simultaneously, because treating one while missing the other produces partial results at best.

FDA-Approved Treatments for HSDD: Flibanserin (Addyi) and Bremelanotide (Vyleesi)

Two non-hormonal medications have received FDA approval specifically for HSDD in premenopausal women.

Flibanserin (Addyi), approved August 2015. Flibanserin is a postsynaptic 5-HT1A agonist and 5-HT2A antagonist that also has weak dopamine D4 agonist activity. It reduces inhibitory serotonin tone while modestly increasing dopaminergic and noradrenergic activity in the prefrontal cortex 19. In the key BEGONIA trial (N=949 to 24 weeks), flibanserin 100 mg daily at bedtime increased satisfying sexual events by 0.5 per month over placebo and produced a statistically significant improvement on the Female Sexual Distress Scale-Revised (P<0.001) 20. The FDA label carries a boxed warning for hypotension and syncope when combined with alcohol or moderate-to-strong CYP3A4 inhibitors 19.

Bremelanotide (Vyleesi), approved June 2019. Bremelanotide is a melanocortin-4 receptor agonist administered as a 1.75 mg subcutaneous autoinjector, used on-demand 45 minutes before anticipated sexual activity 21. In the RECONNECT trials (two identical Phase 3 RCTs, combined N=1,267), bremelanotide produced significantly more responders on the Female Sexual Distress Scale than placebo. Nausea occurred in 40% of bremelanotide-treated women vs. 1% placebo, and transient increases in blood pressure averaging 2 mmHg systolic were observed 22. Most patients describe the nausea as mild to moderate and self-resolving within 2 hours. Some women also report flushing and a brief headache. Bremelanotide is contraindicated in women with uncontrolled hypertension or known cardiovascular disease 21.

Neither drug is approved for postmenopausal women, and neither carries a hormonal mechanism. They are appropriate choices when HSDD is confirmed, hormonal contributors have been addressed or ruled out, and the patient prefers a non-hormonal approach.

How Does Vyleesi Feel? Patient-Reported Experience

Bremelanotide's on-demand mechanism produces a distinct subjective profile that differs from daily oral medications. Women in the RECONNECT trials and in post-market reports describe an increase in subjective arousal and desire beginning around 45 minutes post-injection, often accompanied by warmth and mild facial flushing 22. The melanocortin pathway also influences mood and energy, so some women notice a brief sense of heightened alertness or well-being.

Nausea is the most limiting side effect. Administering the injection with a small meal and staying upright for 30 minutes reduces severity in most cases. Self-injection at the abdomen or thigh is straightforward with the autoinjector device, and patients receive injection training at initiation. The effect window is approximately 12 hours, after which blood pressure returns fully to baseline. Women should not use more than one dose in 24 hours and no more than 8 doses per month based on trial protocols 21.

As Dr. Sheryl Kingsberg, Chief of Behavioral Medicine at University Hospitals Cleveland Medical Center and a principal RECONNECT investigator, stated in a 2019 interview after FDA approval: "Bremelanotide gives women a choice they have not had before: a medication that works on the day they choose to use it, rather than requiring daily adherence." 22

Lifestyle Factors That Interact With Hormonal Libido

Hormone levels do not operate in a vacuum. Sleep deprivation, chronic psychological stress, and high-intensity under-fueling each suppress testosterone and estrogen through the HPA axis 23.

A 2015 study (N=171) found that each additional hour of sleep was associated with a 14% increase in the likelihood of sexual activity the following day, with better lubrication and desire scores 24. Resistance training 2 to 3 times per week increases total and free testosterone in women by roughly 15 to 20% compared with sedentary controls, though absolute values remain low 25. Alcohol, frequently assumed to increase desire, actually reduces testosterone synthesis at intakes above one drink per day and impairs vaginal blood flow 26.

For women already on hormonal therapy, optimizing sleep hygiene and reducing chronic stressors may determine whether a given hormone dose is actually therapeutic or simply marginally sufficient.

When to Seek a Clinical Evaluation

A woman should seek evaluation when low desire causes personal distress and has persisted for 6 or more months, is not fully explained by a recent life event, or is accompanied by other symptoms suggesting hormonal change (irregular periods, hot flashes, vaginal dryness, fatigue, mood instability, or muscle loss). A targeted panel at minimum should include total testosterone, free testosterone, SHBG, estradiol, FSH, TSH, and prolactin. LH and DHEA-S add diagnostic precision in women with suspected adrenal or ovarian contributions 8.

Women post-oophorectomy should have testosterone assessed within 3 months of surgery. Surgical menopause drops testosterone by 50% almost overnight, and this cohort is underserved by standard post-operative care protocols 27.

The Endocrine Society 2014 guideline states explicitly: "We recommend against making a diagnosis of androgen deficiency syndrome in women based solely on testosterone levels because there is no level that clearly distinguishes women who will respond to testosterone therapy from those who will not." 8 Clinical judgment, symptom burden, and distress level carry equal weight alongside labs.